Vendor Intelligence Report: Zhuoyan Peptides

Published 2 Jul 2026. 16-page investigative report on who is behind Zhuoyan Peptides: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 3 pages are free to read on this page.

Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.

Executive summary

Zhuoyan Peptides is not a clean new-vendor story, and not a simple scam finding. The current buyer-facing domain was registered in March 2026, but an associated older domain and PeptideAtlas-listed Janoshik entries place a Zhuoyan-related public footprint back in 2025. The unresolved issue is continuity: the report could not tie the current storefront, older domain, lab-profile trail, and claimed company to the same accountable operator.

Across 2 Finnrick lab tests, Zhuoyan posts 1 pass and 1 fail, for an overall pass rate of 50%. That record is too small to define the whole vendor, but it is not neutral because the only Finnrick-tested product is Retatrutide, where the result points to batch variability and a retest-or-reject posture. PeptideAtlas-listed Janoshik entries make Tirzepatide, SS-31, Epitalon, and a BPC/TB blend better documented than Retatrutide, but only as leads for current-batch verification.

The identity file is the larger buyer-recourse problem. The site names Zhengzhou Zhuoyan Technology Co., Ltd. and sales contacts Sita and Sophia, yet the investigation did not retrieve a matching public registration, owner, executive, street address, business license, payment beneficiary, or invoice issuer. WHOIS records show two privacy-protected domains with different registrars, while PeppyCheck shows an unclaimed, identity-unverified profile and no review history. The X/web coupon sweep found no visible promoter network, which narrows one concern but does not solve accountability.

Inside the full report:

  • Timeline tying WHOIS records, PeptideAtlas entries, Finnrick tests, and July 2026 captures.
  • Corporate-identity verification log for the homepage claim, OpenCorporates result, QCC access gap, and missing ownership/address records.
  • Domain-authenticity analysis of zhuoyan-peptides.com and zyzhuoyanlab.com, including registrar and privacy-protection evidence.
  • Finnrick Retatrutide record, methodology-divergence charts, trajectory view, and Appendix A laboratory data.
  • Reputation review covering PeppyCheck status, Google/Reddit findings, review-platform gaps, and authentication-limited social searches.
  • Affiliate/coupon sweep results and the unresolved TikTok promotion lead.

Risk assessment

  • Unverified corporate-accountability risk — high: Claimed Zhengzhou Zhuoyan Technology Co., Ltd. was not corroborated in OpenCorporates, QCC verification failed, and no owners, executives, or address were retrieved.
  • Retatrutide quality-variability risk — high: Finnrick has 2 Retatrutide tests, 1 pass / 1 fail, with current rating 76.78%; batch-specific COA or retest is essential.
  • Channel-authenticity and domain-fragmentation risk — medium: Current domain registered 2026-03-26, associated alternate domain registered 2025-02-11, both privacy-protected, with no official channel map or anti-counterfeit system documented.
  • Reputation and third-party verification gap — medium: PeppyCheck is unclaimed and identity-unverified with zero reviews, and the investigation retrieved no independent review corpus.